The Latest Breaking News from EMA

NICE says drug is not cost effective and shares fears of side effects

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

Lietz revealed that he at first "had no idea" about the significance of his pass on team-mate Klaus Bachler into Les Combes, which secured victory for the #91 Manthey EMA Porsche he shared with Yasser Shahin and Morris Schuring, as he had begun the final tour in third place.

A total of 20 drivers are competing in the DTM in 2024, representing nine teams and seven different manufacturers.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Growing medical needs, surging demand for precision medicine, favorable regulatory climate, and rapid digital transformation would create promising growth opportunities for pharma companies. Hence, it could be wise to invest in top pharma stocks Johnson & Johnson (JNJ), Spero Therapeutics (SPRO), Ipsen (IPSEY), and Procaps Group (PROC) for solid gains.…

Shahin and Morris Schuring will pair up with Manthey’s designated Pro driver Richard Lietz at the wheel of the #91 Porsche 911 GT3 R (Type 992) that will be run in collaboration with EMA in the new LMGT3 class.

Amid a growing remote workforce, IT teams are challenged to provide a smooth Wi-Fi experience.

Hold onto your hats, folks, because there's some fascinating news in the world of diabetes and obesity drugs! A recent federal study found that people taki...